Healthcare provider profile · identity verified

Howard E. Huey, D.O.

Endocrinology · NEW YORK, NY · NPI 1619951175

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Metformin Hcl Er	Metformin Hcl	568	138
Levothyroxine Sodium	Levothyroxine Sodium	449	113
Ozempic	Semaglutide	390	74
Glimepiride	Glimepiride	295	57
Atorvastatin Calcium	Atorvastatin Calcium	240	67
Synthroid	Levothyroxine Sodium	194	40
Farxiga	Dapagliflozin Propanediol	185	42
Jardiance	Empagliflozin	167	39
Losartan Potassium	Losartan Potassium	165	46
Methimazole	Methimazole	147	32
Januvia	Sitagliptin Phosphate	113	33
Tradjenta	Linagliptin	113	25
Rybelsus	Semaglutide	105	27
Rosuvastatin Calcium	Rosuvastatin Calcium	102	31
Ezetimibe	Ezetimibe	98	22
Pioglitazone Hcl	Pioglitazone Hcl	89	28
Glipizide Er	Glipizide	83	23
Metformin Hcl	Metformin Hcl	83	29
Alcohol Prep Pads	Alcohol Antiseptic Pads	82	43
Potassium Chloride	Potassium Chloride	82	17
Repaglinide	Repaglinide	80	19
Glipizide	Glipizide	74	17
Tresiba Flextouch U-100	Insulin Degludec	67	20
Ammonium Lactate	Ammonium Lactate	61	12
Invokana	Canagliflozin	51	suppressed
Mounjaro	Tirzepatide	50	suppressed
Novolog Mix 70-30 Flexpen	Insulin Aspart Prot/Insuln Asp	48	suppressed
Amlodipine Besylate	Amlodipine Besylate	47	12
Trulicity	Dulaglutide	44	11
Toujeo Solostar	Insulin Glargine,hum.Rec.Anlog	37	suppressed
Allopurinol	Allopurinol	36	suppressed
Humulin R U-500 Kwikpen	Insulin Regular, Human	36	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	36	13
Ultra-Fine Nano Pen Needle	Pen Needle, Diabetic	36	13
Famotidine	Famotidine	33	suppressed
Basaglar Kwikpen U-100	Insulin Glargine,hum.Rec.Anlog	31	suppressed
Easy Touch Alcohol Prep Pads	Alcohol Antiseptic Pads	29	14
Fenofibrate	Fenofibrate Nanocrystallized	28	suppressed
Janumet	Sitagliptin Phos/Metformin Hcl	28	suppressed
Comfort Ez Pen Needle	Pen Needle, Diabetic	27	suppressed
Cycloset	Bromocriptine Mesylate	27	suppressed
Icosapent Ethyl	Icosapent Ethyl	27	suppressed
Gabapentin	Gabapentin	26	suppressed
Alendronate Sodium	Alendronate Sodium	25	suppressed
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	25	12
Raloxifene Hcl	Raloxifene Hcl	25	suppressed
Alcohol Pads	Alcohol Antiseptic Pads	24	11
Simvastatin	Simvastatin	24	suppressed
Calcitriol	Calcitriol	23	suppressed
Hydrocortisone	Hydrocortisone	21	suppressed
Montelukast Sodium	Montelukast Sodium	21	suppressed
Tamsulosin Hcl	Tamsulosin Hcl	21	suppressed
Humalog Mix 50-50 Kwikpen	Insulin Lispro Protamin/Lispro	19	suppressed
Liothyronine Sodium	Liothyronine Sodium	19	suppressed
Clopidogrel	Clopidogrel Bisulfate	17	suppressed
Omeprazole	Omeprazole	17	suppressed
Prolia	Denosumab	17	15
Testosterone	Testosterone	17	suppressed
Tresiba Flextouch U-200	Insulin Degludec	17	suppressed
Ultra-Fine Mini Pen Needle	Pen Needle, Diabetic	17	suppressed
Dapagliflozin	Dapagliflozin Propanediol	16	suppressed
Humalog Mix 75-25 Kwikpen	Insulin Lispro Protamin/Lispro	16	suppressed
Meclizine Hcl	Meclizine Hcl	16	suppressed
Fentanyl	Fentanyl	15	suppressed
Fluconazole	Fluconazole	15	suppressed
Lisinopril	Lisinopril	15	suppressed
Vascepa	Icosapent Ethyl	15	suppressed
Cinacalcet Hcl	Cinacalcet Hcl	14	suppressed
Spironolactone	Spironolactone	14	suppressed
Easy Comfort Pen Needles	Pen Needle, Diabetic	13	suppressed
Semglee (Yfgn) Pen	Insulin Glargine-Yfgn	13	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	13	suppressed
Furosemide	Furosemide	12	suppressed
Humalog Kwikpen U-100	Insulin Lispro	12	suppressed
Metoprolol Succinate	Metoprolol Succinate	12	suppressed
Potassium Citrate Er	Potassium Citrate	12	suppressed
Albuterol Sulfate Hfa	Albuterol Sulfate	11	suppressed
Hydrochlorothiazide	Hydrochlorothiazide	11	suppressed
Telmisartan	Telmisartan	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error